amri
Complex Science. Expert Solutions.

2017 Annual Meeting of Stockholders

May 31, 2017

Forward Looking Statements

This presentation and oral statements made by the Company may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by forward-looking words such as “may,” “could,” “should,” “would,” “will,” “plans,” “intend,” “expect,” “anticipate,” “predicts,” “potential,” “believe,” “continue” or similar words, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements regarding financial estimates and projections for 2017, 2018 and any future years, statements about our ability to become a top five global CDMO, statements concerning our recent acquisitions and the financial impact and expected synergies of each, and statements regarding the impact of pending litigation matters, government regulation, customer spending and business trends, competition, foreign operations, business growth and the expansion of the global market, management’s strategic plans, the potential for future revenue under our co-development agreements, research and development projects and expenses, other projected costs, long-lived asset and goodwill impairment, our ability to utilize deferred tax assets, pension and postretirement benefit costs, and tax rates.

Readers should not place undue reliance on these forward-looking statements. Our actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which we may not be able to predict and may not be within our control. Factors that could cause such differences include, but are not limited to, changes in customers’ spending and demand and the trends in pharmaceutical and biotechnology companies’ outsourcing of manufacturing services and research and development; our ability to provide quality and timely services and to compete with other companies providing similar services; our ability to comply with strict regulatory requirements; our ability to successfully integrate past and future acquisitions and to realize the expected benefits of each; disruptions in our ability to source raw materials; a change in our relationships with our largest customers; our ability to service our indebtedness; our ability to protect our technology and proprietary information and the confidential information of our customers; our ability to develop products of commercial value under our co-development agreements; the risk of patent infringement and other litigation, as well as those risks discussed elsewhere in our public filings, including those found under “Risk Factors” in our Annual Report on Form 10-K and other periodic reports filed by the Company. All forward-looking statements are made as of the date hereof and we do not undertake any obligation to update our forward-looking statements, except as required by applicable law.

amri
Complex Science. Expert Solutions.

Non-GAAP Financial Measures

To supplement our financial results prepared in accordance with U.S. GAAP, we have presented non-GAAP measures of contract gross profit, contract gross margin, gross profit, gross margin, SG&A, net income, and earnings per diluted share, adjusted to exclude certain charges (and gains when applicable) that relate to specific events or transactions, such as impairment charges, restructuring charges, executive transition costs, business acquisition costs, realized and unrealized gains and losses on foreign currency transactions related to business acquisitions, and ERP implementation costs. Management typically excludes these amounts when evaluating our operating performance and believes that the resulting non-GAAP measures provide investors with a consistent basis for comparison across periods and, therefore, are useful to investors in assessing our operating performance.

Our U.S. GAAP measures are also adjusted to exclude certain non-cash charges (and gains when applicable) such as non-cash debt interest and amortization charges, share-based compensation expense, acquisition accounting inventory adjustments, and acquisition accounting depreciation and amortization for the periods presented for 2017 and 2016. Management typically excludes the amounts described above when evaluating our operating performance and believes that the resulting non-GAAP measures are useful to investors in assessing our operating performance.

We have also presented the non-GAAP measure of adjusted EBITDA, which in addition to the items excluded above, further excludes the impact of interest income and expense, depreciation and amortization expense, and income tax expense or benefit.

We believe presentation of our non-GAAP measures enhances an overall understanding of our historical financial performance because we believe these measures are an indication of the performance of our base business. Management uses these non-GAAP measures as a basis for evaluating our financial performance as well as for budgeting and forecasting of future periods. For these reasons, we believe they can be useful to investors. The presentation of this additional information should not be considered in isolation or as a substitute for the related GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are set forth in the Appendix and in our historical earnings releases.

A reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures has been included in the Appendix.

AMRI has Built a Scalable, Global Business Providing Contract Research, Testing and Manufacturing Services to the Biopharmaceutical Industry

Focused on complex science and challenging technology

25 year pedigree of servicing the pharmaceutical industry

3,100 employees globally with capacity for small and large projects

7 acquisitions in 3 years from 2014 – 2016 to rapidly scale capabilities and operations network

amri
Complex Science. Expert Solutions.

Distinct Business Unit Strategies Providing Integrated Services to Biopharma



amri
Complex Science. Expert Solutions.

* Midpoint of guidance as of May 9, 2017.

Acquisitions Strengthened Service Offerings in Complex Science



amri
Complex Science. Expert Solutions.

AMRI Has Made Significant Progress Since Embarking On Its New Corporate Strategy in 2014

2010 – 2013

- Profitability driven from Allegra royalty stream
- CDMO cash flow used to fund proprietary pipeline
- High customer concentration
- Focus on US market

2014 – 2016 and Beyond

- Increased focus on improving profitability and organic growth
- Acquired and integrated 7 companies, nearly tripling Adjusted EBITDA
- Evolved into global API supplier with substantial European footprint
- Launch of generic co-development alliances

($ in millions)



* Midpoint of guidance as of May 9, 2017.

amri
Complex Science. Expert Solutions.

AMRI Has Transitioned From Being a Royalty Driven CRO to a Diversified Growth CDMO



2010 - 2013

- Unprofitable even with Allegra royalties
- Despite restructuring actions, Allegra still responsible for bulk of profits in 2013

2014 - 2017

- Organic and inorganic growth has delivered on the strategic plan
- Despite expiration of Allegra royalties in Q3 2015, non-GAAP operating margins have continued to expand

* Midpoint of guidance as of May 9, 2017. Please refer to the Appendix and our historical earnings press releases for a reconciliation of non-GAAP items.

amri
Complex Science. Expert Solutions.

A Diversified Customer and Revenue Base

Top 30(1) = 49% of business
Top 10(1) = 32% of business

>3,100 employees world wide in 7 countries

$687M Revenue(1)
Top 10 Global CDMO

Segment Mix(2)



Geographic Mix(3)



Allergan · astellas (Leading Light for Life) · Bristol-Myers Squibb · endo · GE · GILEAD · Lilly · MERCK · Mylan · Pfizer · Shire · Takeda · TEVA

(1) *Pro forma 2016, including Euticals for a full year.*
(2) *Based on 2017E contract revenue.*
(3) *Reflects pro forma 9 month 2016 customer mix by geographic region.*

amri
Complex Science. Expert Solutions.

AMRI Has Established the Foundation for a Scalable Platform



amri
Complex Science. Expert Solutions.

AMRI is on a Clear Path to Becoming a Top 5 Global CDMO

-- Future Drivers of AMRI's Continued Growth

Outsourcing for API and drug product manufacturing **still in its infancy**

44 Phase 3 programs fuel pipeline for commercial contracts

12 co-development deals with partners create $150-200M in royalty opportunity through 2020

M&A strategy focused on expanding capabilities in complex science

Targeting a run rate of **$1B** in revenues in 2018

amri
Complex Science. Expert Solutions.

AMRI is Ahead of a Market Shifting Towards Increased Outsourcing

- CDMO Market is Larger, Less Penetrated -

~50% Outsourced

Clinical Research Organizations (CROs)



$53B Addressable Market

Top 7 CROs have ~60% market share

~30% Outsourced

Contract Development and Manufacturing Organizations (CDMOs)



$140B Addressable Market

Top 15 CDMOs have ~35% market share

Figures from Root Analysis, Evaluate Pharma and publicly available reports.

amri
Complex Science. Expert Solutions.

Well Positioned to Capitalize on Market Trends

High Potency API Global Revenue Projected to Double from 2015-2020

($ in billions)



AMRI is a leading High Potency API global player

- Cytotoxics
- Steroids
- Hormones
- Controlled Substances
- Large scale hydrogenation, bromination and fermentation capability

Source: Grand View Research, "High Potency Active Pharmaceutical Ingredients (HPAPI) Market Worth $25.86 Billion by 2022" (Summary) – Oct 2015.

amri
Complex Science. Expert Solutions.

Providing Services at All Stages of Development Creates Sticky Customers



Generic Development refers to either 505b2 or ANDA – generics.

amri
Complex Science. Expert Solutions.

AMRI Touches >10% of Industry Small Molecules in Early Development



Source: IMS Lifecycle R&D Focus (December 2015).

amri
Complex Science. Expert Solutions.

Biologics are an Expanding Portion of Early Stage Pipelines

- While late stage pipelines orient towards small molecules, more biologics are emerging in early-stage pipeline
- While Big Pharma and Big Biotech companies have been investing in biologics manufacturing capacity, smaller Biotech companies will depend on CDMOs to fulfill their bio-manufacturing needs



Source: IMS Lifecycle R&D Focus (December 2015).

amri
Complex Science. Expert Solutions.

Industry Pipelines Aligned with Our Strengths in Complex Science

Over half of finished drug pipeline projects are delivered via a sterile form



Note: Values represent the number of pipeline projects by delivery route.

Source: 2016 Pharmaprojects Pharma R&D Annual Review (April 2016)

amri
Complex Science. Expert Solutions.

Generic Product Co-Development Alliances Potentially Add Up to $150-$200M of Royalties by 2020

12 Generic co-development programs, touching all of our core businesses

- Co-investment on API and/or Drug Product development
- AMRI to manufacture commercial supply
- AMRI to share profits on partner's sales

First Product Launched:

Sodium Nitroprusside (Nitropress®)

amri
Complex Science. Expert Solutions.

Taking AMRI to the Next Level

Growth Strategies

Near-Term (2017 Priority)

- Maximize synergies from Euticals and prior 6 acquisitions
- API: Second sterile site in Spain
- Leverage capacity across network
- Optimize Fine Chemicals
- DDS: Expand analytical services offerings
- Ramp up of Buffalo integrated discovery site
- Establish DDS services in Spain

Medium-Term (1-3 Years)

- Secure biologic and peptide capabilities
- DDS: Add additional analytical testing services, potential for European discovery site
- DP: Add new complex dosage forms - Inhalation, liquids, creams & ointments, patches & thin film
- DP: Increase presence in sterile, i.e. Blow-Fill-Seal (BFS) manufacturing

Long-Term (3-5 years)

- Become top tier global CDMO
- Target $1B+ of revenues
- Continue to pursue co-development royalty opportunities

Path forward

Organic: Continued capital expenditures and research & development investments to drive growth

Inorganic: Expand key capabilities and enter attractive areas with high barriers to entry

amri
Complex Science. Expert Solutions.

Thank You

Appendix

amri
Complex Science. Expert Solutions.

A Powerful Network of >3,100 Employees Globally Across 21 Sites



Discovery & Development[1]		API Manufacturing[1]		Drug Product	
West Lafayette, IN	Frankfurt, Germany	Springfield, MO	Origgio, Italy	Burlington, MA	Glasgow, UK
Lebanon, NJ	Hyderabad, India	Grafton, WI	Rozzano, Italy	Albuquerque, NM	Leon, Spain
Albany, NY		Rensselaer, NY	Léon, Spain		
Buffalo, NY		Bon-Encontre, France	San Cristobal, Spain		
		Tonneins, France	Valladolid, Spain		
		Aurangabad, India			
		Lodi, Italy			

Note: Does not include DDS facility in Singapore which is scheduled for closure in 2H 2017 and Malta API facility.
(1) Fine Chemicals manufacturing operations at Springfield, Frankfurt, Lodi, Orrigio, Rozzano, Bon-Encontre and Tonneins facilities.

amri
Complex Science. Expert Solutions.

We Have Achieved Scale and a Track Record of Growth and Operational Excellence

Revenue



Adjusted EBITDA(1)



2017E represents midpoint of guidance as of 5/9/17.

(1) 2014 based upon Adj. EBITDA plus add-back for non-cash stock-based compensation.

**Please refer to historical filings and the Appendix for a reconciliation of non-GAAP items*

amri
Complex Science. Expert Solutions.

AMRI Capitalization and Debt ($ in millions)

	March 31, 2017	December 31, 2016
Term B Loan[1]	425	426
Seller Notes[2]	59	58
2018 Cash Convertible Sr. Notes[3]	150	150
Revolver	0	0
Other Debt	45	49
Total Debt	679	684
Cash & Equivalents	35	51
Net Debt	644	633
Leverage	5.7	5.9

[1]LIBOR plus 4.75% with floor of 1%
[2]Interest @ 0.25% annually payable in three annual installments beginning in 2019
[3]Interest @ 2.25% annually

amri
Complex Science. Expert Solutions.

AMRI Key Financial Metrics

$ millions

	2010	2011	2012	2013	2014	2015	2016
Total Revenue	$198.0	$207.6	$226.7	$246.6	$276.6	$402.4	$570.5
% growth	—	4.8%	9.2%	8.8%	12.2%	45.5%	41.8%
Adjusted EBITDA[1]	$9.5	$5.8	$31.5	$49.1	$50.0	$75.2	$102.0
% margin	4.8%	2.8%	13.9%	19.9%	18.1%	18.7%	17.9%
Cash & Equivalents[2]	$41.5	$20.2	$28.5	$180.5	$51.0	$52.3	$52.0
Debt	$13.2	$5.8	$8.0	$163.4	$187.7	$421.5	$683.5
Net Debt	($28.3)	($14.4)	($20.5)	($17.1)	$136.7	$369.2	$631.5

Solid financial footing with increasingly attractive profile

1) Please refer to our 4Q and fiscal year end earnings releases for a reconciliation of non-GAAP items: http://ir.amriglobal.com/results.cfm
2) Cash and cash equivalents includes restricted cash

amri
Complex Science. Expert Solutions.

Adjusted EBITDA Reconciliation for 4Q and FY 2015 and 2016

(Dollars in thousands)

	Three months ended December 31, 2016	Three months ended December 31, 2015	Twelve months ended December 31, 2016	Twelve months ended December 31, 2015
Net (loss) income, as reported	$ (15,412)	$ 1,785	$ (70,171)	$ (2,301)
Income tax expense (benefit)	2,920	(2,030)	10,212	(1,168)
Interest expense, net	13,009	6,806	39,923	19,338
Depreciation and amortization	17,774	8,421	47,865	27,091
EBITDA	18,292	14,982	27,829	42,960
Impairment charges	2,925	615	3,126	3,770
Restructuring and other charges	4,158	1,382	10,252	5,210
Executive transition costs	-	7	7	1,412
Business acquisition costs	1,304	2,362	13,559	5,664
Purchase accounting inventory adjustments	13,766	5,026	33,347	8,107
ERP Implementation costs	1,012	660	4,661	1,425
Non-recurring professional fees	130	66	730	892
Share-based compensation expense	2,066	1,555	8,430	6,371
Insurance recovery	(7,385)	-	(7,385)	(600)
Gain on sale of facility	-	-	(158)	-
Foreign exchange loss on acquisition	-	-	7,180	-
Legal settlement	406	-	406	-
Adjusted EBITDA	$ 36,675	$ 26,655	$ 101,985	$ 75,211

amri
Complex Science. Expert Solutions.

Reconciliation of 4Q and FY 2015 and 2016 Contract Gross Profit and Contract Gross Margin

(Dollars in thousands)

Non-GAAP Measures (Dollars in thousands)	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2016	2015	2016	2015
Consolidated Contract Revenue, as reported	$ 189,454	$ 123,032	$ 560,430	$ 384,738
Consolidated Cost of Contract Revenue, as reported	152,586	92,516	437,649	295,527
Consolidated Contract Gross Profit, as reported	36,868	30,516	122,781	89,211
add: Share-based compensation expense	239	213	1,159	936
add: Acquisition accounting inventory adjustments	13,766	5,026	33,347	8,107
add: Acquisition accounting depreciation	6,276	615	11,785	2,661
add: Business acquisition costs	-	289	-	289
Non-GAAP Consolidated Contract Gross Profit	$ 57,150	$ 36,659	$ 169,073	$ 101,204
Consolidated Contract Gross Margin, as reported	19.5%	24.8%	21.9%	23.2%
Non-GAAP Consolidated Contract Gross Margin	30.2%	29.8%	30.2%	26.3%
DDS Segment Contract Revenue, as reported	$ 26,984	$ 22,325	$ 104,472	$ 83,059
DDS Segment Cost of Contract Revenue, as reported	16,652	16,045	70,430	61,180
DDS Segment Contract Gross Profit, as reported	10,332	6,280	34,042	21,879
add: Share-based compensation expense	130	146	882	595
add: Acquisition accounting inventory adjustments	(253)	-	(54)	-
add: Acquisition accounting depreciation	259	310	1,104	1,023
Non-GAAP DDS Segment Contract Gross Profit	$ 10,468	$ 6,736	$ 35,974	$ 23,497
DDS Segment Contract Gross Margin, as reported	38.3%	28.1%	32.6%	26.3%
Non-GAAP DDS Segment Contract Gross Margin	38.8%	30.2%	34.4%	28.3%
API Segment Contract Revenue, as reported	$ 128,120	$ 70,867	$ 337,835	$ 204,868
API Segment Cost of Contract Revenue, as reported	107,640	54,243	272,867	154,670
API Segment Contract Gross Profit, as reported	20,479	16,624	64,967	50,198
add: Share-based compensation expense	62	41	231	230
add: Acquisition accounting inventory adjustments	14,090	5,026	31,111	8,107
add: Acquisition accounting depreciation	5,323	48	8,882	665
Non-GAAP API Segment Contract Gross Profit	$ 39,954	$ 21,739	$ 105,191	$ 59,200
API Segment Contract Gross Margin, as reported	16.0%	23.5%	19.2%	24.5%
Non-GAAP API Segment Contract Gross Margin	31.2%	30.7%	31.1%	28.9%
DP Segment Contract Revenue, as reported	$ 23,705	$ 29,841	$ 98,377	$ 96,810
DP Segment Cost of Contract Revenue, as reported	19,643	22,228	76,343	79,677
DP Segment Contract Gross Profit, as reported	4,062	7,613	22,033	17,133
add: Share-based compensation expense	47	26	122	111
add: Acquisition accounting depreciation	63	257	545	973
add: Business acqusition costs	-	289	-	289
Non-GAAP DP Segment Contract Gross Profit	$ 4,173	$ 8,185	$ 22,701	$ 18,506
DP Segment Contract Gross Margin, as reported	17.1%	25.5%	22.4%	17.7%
Non-GAAP DP Segment Contract Gross Margin	17.6%	27.4%	23.1%	19.1%
FC Segment Contract Revenue, as reported	$ 10,644	$ -	$ 19,745	$ -
FC Segment Cost of Contract Revenue, as reported	8,650	-	18,008	-
FC Segment Contract Gross Profit, as reported	1,994	-	1,736	-
add: Acquisition accounting inventory adjustments	(71)		2,290	
add: Acquisition accounting depreciation	630	-	913	-
Non-GAAP FC Segment Contract Gross Profit	$ 2,554	$ -	$ 4,940	$ -
FC Segment Contract Gross Margin, as reported	18.7%	-	8.8%	-
Non-GAAP FC Segment Contract Gross Margin	24.0%	-	25.0%	-

amri
Complex Science. Expert Solutions.

Reconciliation of Non-GAAP Measures: 4Q and FY 2015 and 2016

(Dollars in thousands, except per share data)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2016	2015	2016	2015
Consolidated net (loss) income, as reported	$ (15,412)	$ 1,785	$ (70,171)	$ (2,301)
Share-based compensation expense	2,066	1,555	8,430	6,371
Acquisition accounting inventory adjustments	13,766	5,026	33,347	8,107
Acquisition accounting depreciation and amortization	8,884	2,337	21,038	7,094
Intellectual property impairment	-	-	201	-
Income tax effects of Non-GAAP adjustments	(2,084)	(5,180)	(12,365)	(13,785)
Non-recurring income tax adjustments	-	-	8,467	-
Non-cash interst and amortization charges	5,067	2,712	15,972	8,932
Foreign exchange loss on business acquisition	-	-	7,180	-
Gain on sale of Syracuse facility	-	-	(158)	-
Insurance recovery	(7,385)	-	(7,385)	(600)
Restructuring and other charges	7,094	2,775	13,188	9,758
Business acquistion costs	1,304	2,362	13,559	5,664
Executive transition charges	-	7	7	1,412
ERP implementation costs	1,012	660	4,661	1,425
Non-recurring professional fees	130	66	730	892
Legal settlement	406	-	406	-
Non-GAAP net income	$ 14,848	$ 14,105	$ 37,106	$ 32,969
Consolidated Basic (loss) earnings per share, as reported	$ (0.37)	$ 0.05	$ (1.83)	$ (0.07)
Effects of Non-GAAP adjustments	0.72	0.36	2.80	1.06
Non-GAAP Basic earnings per share	$ 0.35	$ 0.41	$ 0.97	$ 0.99
Consolidated Diluted (loss) earnings per share, as reported	$ (0.37)	$ 0.05	$ (1.83)	$ (0.07)
Effects of Non-GAAP adjustments	0.71	0.35	2.78	1.03
Non-GAAP Diluted earnings per share	$ 0.34	$ 0.40	$ 0.95	$ 0.96
Consolidated Cost of Contract Revenue, as reported	$ 152,586	$ 92,516	$ 437,649	$ 295,527
Share-based compensation expense	(239)	(213)	(1,159)	(936)
Acquisition accounting inventory adjustments	(13,766)	(5,026)	(33,347)	(8,107)
Acquisition accounting depreciation and amortization	(6,276)	(615)	(11,785)	(2,661)
Business acquisition costs	-	(289)	-	(289)
Non-GAAP Cost of Contract Revenue	$ 132,304	$ 86,373	$ 391,357	$ 283,534

amri
Complex Science. Expert Solutions.

Reconciliation of Non-GAAP Measures: 4Q and FY 2015 and 2016 (Cont'd)

(Dollars in thousands, except per share data)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2016	2015	2016	2015
Consolidated Research and Development, as reported	$ 4,757	$ 2,160	$ 10,252	$ 5,988
Acquisition accounting depreciation and amortization	173	-	64	-
Non-GAAP Research and development	$ 4,930	$ 2,160	$ 10,316	$ 5,988
Consolidated Selling, general and administrative, as reported	$ 32,308	$ 22,183	$ 122,136	$ 77,394
Acquisition accounting depreciation and amortization	(2,780)	(1,722)	(9,316)	(4,433)
Share-based compensation expense	(1,827)	(1,342)	(7,271)	(5,435)
Business acquistion costs	(1,306)	(2,073)	(13,561)	(5,375)
Executive transition charges	-	(7)	(7)	(1,412)
ERP implementation costs	(1,012)	(660)	(4,661)	(1,425)
Non-recurring professional fees	(130)	(66)	(730)	(892)
Legal settlement	(406)	-	(406)	-
Non-GAAP Selling, general and administrative	$ 24,847	$ 16,313	$ 86,184	$ 58,422
Consolidated Interest expense, as reported	$ (13,009)	$ (6,806)	$ (39,923)	$ (19,338)
Non-cash interest and amortization charges	5,067	2,712	15,972	8,932
Non-GAAP Interest expense	$ (7,943)	$ (4,094)	$ (23,952)	$ (10,406)
Consolidated Other income (expense), as reported	$ 5,930	$ 319	$ (1,276)	$ 2,220
Foreign exchange loss on business acquisition	-	-	7,180	-
Gain on sale of Syracuse facility	-	-	(158)	-
Insurance recovery	(7,387)	-	(7,387)	(600)
Non-GAAP Other (expense) income	$ (1,457)	$ 319	$ (1,641)	$ 1,620

amri
Complex Science. Expert Solutions.

Reconciliation of Forward-Looking 2017 Non-GAAP Financial Measures to Forward-Looking GAAP Financial Measures (Dollars in thousands, except per share data)

Reconciliation of GAAP net loss and GAAP diluted loss per share to non-GAAP net income and non-GAAP diluted earnings per share (Dollars in millions, except per share amounts)

	Low	High
GAAP net loss	$ (12)	$ (7)
Reconciling items (a)	$ 59	$ 59
Non-GAAP net income	$ 47	$ 52
GAAP diluted loss per share	$ (0.28)	$ (0.16)
Non-GAAP diluted earnings per share	$ 1.08	$ 1.20

(a) Reconciling items primarily include restructuring costs, acquisition accounting depreciation and amortization, share-based compensation, non-cash debt interest and amortization charges and the tax effect for such items.

Reconciliation of GAAP net loss to Adjusted EBITDA (Dollars in millions)

	Low	High
GAAP net loss	$ (12)	$ (7)
Income tax (benefit) expense	$ 12	$ 13
Interest expense, net	$ 48	$ 48
Depreciation and amortization	$ 62	$ 66
EBITDA	$ 110	$ 121
Reconciling items (b)	$ 24	$ 24
Adjusted EBITDA	$ 135	$ 145

(b) Reconciling items primarily include restructuring costs, share-based compensation charges and the tax effect of all non-gaap reconciling items.

Reconciliation of GAAP contract gross margin to non-GAAP contract gross margin

GAAP contract gross margin	26%
Add: acquisition accounting depreciation and share-based compensation	3%
Non-GAAP contract gross margin	29%

Reconciliation of GAAP SG&A as a percentage of contract revenue to non-GAAP SG&A as a percentage of contract revenue

GAAP Selling, General and Administrative Expense	18%
Reconciling items (c)	(3%)
Non-GAAP Selling, General, and Administrative Expense	15%

(c) Reconciling items primarily include acquisition accounting depreciation and amortization and share-based compensation.

amri
Complex Science. Expert Solutions.

About AMRI

- Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, *in vitro* biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports pre-clinical through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

Contacts:

- Investor Relations: Patty Eisenhaur, AMRI Investor Relations, 518-512-2261
- Media: Gina Rothe, AMRI Communications, 518-512-2512

amri
Complex Science. Expert Solutions.